Document is current

Any future updates will be listed below

Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system

Crossref DOI link: https://doi.org/10.1038/s41598-025-92741-y

Published Online: 2025-03-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark